Effects of fibrates on human organic anion-transporting polypeptide 1B1-, multidrug resistance protein 2- and P-glycoprotein-mediated transport
- 1 July 2005
- journal article
- research article
- Published by Taylor & Francis in Xenobiotica
- Vol. 35 (7) , 737-753
- https://doi.org/10.1080/00498250500136676
Abstract
The effects of different fibric acid derivatives (bezafibrate, clofibrate, clofibric acid, fenofibrate, fenofibric acid and gemfibrozil) on human organic anion transporting-polypeptide 1B1 (OATP2, OATP-C, SLC21A6), multidrug resistance protein 2 (MRP2/ABCC2) and MDR1-type P-glycoprotein (P-gp/ABCB1) were examined in vitro. Cyclosporin A (a known inhibitor of OATP1B1 and P-gp), MK-571 (a known inhibitor of MRP2) and cimetidine (an organic cation) were also tested. Bezafibrate, fenofibrate, fenofibric acid and gemfibrozil showed concentration-dependent inhibition of estradiol 17-β-D-glucuronide uptake by OATP1B1-stably transfected HEK cells, whereas clofibrate and clofibric acid did not show any significant effects up to 100 µM. Inhibition kinetics of gemfibrozil, which exhibited the most significant inhibition on OATP1B1, was shown to be competitive with a Ki = 12.5 µM. None of the fibrates showed any significant inhibition of MRP2-mediated transport, which was evaluated by measuring the uptake of ethacrynic acid glutathione into MRP2-expressing Sf9 membrane vesicles. Only fenofibrate showed moderate P-gp inhibition as assessed by measuring cellular accumulation of vinblastine in a P-gp overexpressing cell-line. Cyclosporin A significantly inhibited OATP1B1 and P-gp, whereas only moderate inhibition was observed on MRP2. The rank order of inhibitory potency of MK-571 was determined as OATP1B1 (IC50: 0.3 µM) > MRP2 (4 µM) > P-gp (25 µM). Cimetidine did not show any effects on these transporters. In conclusion, neither MRP2- nor P-gp-mediated transport is inhibited significantly by the fibrates tested. Considering the plasma protein binding and IC50 values for OATP1B1, only gemfibrozil appeared to have a potential to cause drug–drug interactions by inhibiting OATP1B1 at clinically relevant concentrations.Keywords
This publication has 36 references indexed in Scilit:
- Risk of adverse events with fibratesThe American Journal of Cardiology, 2004
- Transport of Ethinylestradiol Glucuronide and Ethinylestradiol Sulfate by the Multidrug Resistance Proteins MRP1, MRP2, and MRP3The Journal of Pharmacology and Experimental Therapeutics, 2004
- Influence of lipid lowering fibrates on P-glycoprotein activity in vitroBiochemical Pharmacology, 2003
- Characterization of the transport of the bicyclic peptide phalloidin by human hepatic transport proteinsNaunyn-Schmiedebergs Archiv für experimentelle Pathologie und Pharmakologie, 2003
- Characterization of the Transport Properties of Human Multidrug Resistance Protein 7 (MRP7, ABCC10)Molecular Pharmacology, 2003
- Gemfibrozil greatly increases plasma concentrations of cerivastatinClinical Pharmacology & Therapeutics, 2002
- Reconstitution of Transport-Active Multidrug Resistance Protein 2 (MRP2; ABCC2) in ProteoliposomesBiological Chemistry, 2002
- Plasma concentrations of active simvastatin acid are increased by gemfibrozilClinical Pharmacology & Therapeutics, 2000
- Steady-state kinetics of bezafibrate and clofibrate in healthy female volunteersEuropean Journal of Clinical Pharmacology, 1980
- Clofibrate disposition in renal failure and acute and chronic liver diseaseEuropean Journal of Clinical Pharmacology, 1979